Peter Lawson
Stock Analyst at Barclays
(1.21)
# 3,530
Out of 4,876 analysts
109
Total ratings
34.48%
Success rate
-14.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.27 | +136.22% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.10 | +81.82% | 4 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $1 → $0.46 | $0.24 | +89.93% | 3 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $4.49 | +122.72% | 3 | May 13, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $5 → $4 | $1.74 | +129.89% | 7 | May 12, 2025 | |
| XNCR Xencor | Maintains: Underweight | $22 → $6 | $8.40 | -28.57% | 2 | May 8, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $32 → $11 | $5.73 | +91.97% | 1 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $32 → $16 | $7.80 | +105.13% | 8 | May 2, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Overweight | $40 → $15 | $7.30 | +105.48% | 2 | May 1, 2025 | |
| SWTX SpringWorks Therapeutics | Downgrades: Equal-Weight | $63 → $47 | $46.99 | +0.02% | 4 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $8.53 | +64.22% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.99 | +50.75% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.48 | +102.70% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.53 | +161.44% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $29 | $43.09 | -32.70% | 5 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $37.48 | +60.09% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $3.32 | +412.05% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $9.29 | +255.22% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $32.02 | +106.12% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $105 | $128.15 | -18.06% | 10 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $11.83 | +162.05% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $9.46 | +79.70% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $4.92 | +164.23% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.86 | +481.40% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $2.31 | +51.52% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $94.16 | +287.64% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $33.65 | +36.70% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $29.68 | +1,416.17% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.12 | +2,022.64% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $46.70 | -3.64% | 2 | Jan 23, 2018 |
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.27
Upside: +136.22%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.10
Upside: +81.82%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Underweight
Price Target: $1 → $0.46
Current: $0.24
Upside: +89.93%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $4.49
Upside: +122.72%
Iovance Biotherapeutics
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $1.74
Upside: +129.89%
Xencor
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $8.40
Upside: -28.57%
Kura Oncology
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $5.73
Upside: +91.97%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $7.80
Upside: +105.13%
Bicycle Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $7.30
Upside: +105.48%
SpringWorks Therapeutics
Apr 28, 2025
Downgrades: Equal-Weight
Price Target: $63 → $47
Current: $46.99
Upside: +0.02%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $8.53
Upside: +64.22%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.99
Upside: +50.75%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.48
Upside: +102.70%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.53
Upside: +161.44%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $25 → $29
Current: $43.09
Upside: -32.70%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $37.48
Upside: +60.09%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $3.32
Upside: +412.05%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $9.29
Upside: +255.22%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $32.02
Upside: +106.12%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $75 → $105
Current: $128.15
Upside: -18.06%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $11.83
Upside: +162.05%
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $9.46
Upside: +79.70%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $4.92
Upside: +164.23%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.86
Upside: +481.40%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.31
Upside: +51.52%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $94.16
Upside: +287.64%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $33.65
Upside: +36.70%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $29.68
Upside: +1,416.17%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.12
Upside: +2,022.64%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $46.70
Upside: -3.64%